Skip to main content
Signal8

ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing

$PMNPress releaseNov 12, 2026, 4:05 PM ET

ProMIS Neurosciences reported a Q3 2026 net loss of $8.2 million, or $(0.89) per share, with cash of $44.1 million as of September 30, 2026. The company reaffirmed that PRECISE-AD Phase 1b topline data for PMN310 remains on track for Q1 2027, and said cash funds operations through 2027 — beyond the readout. Interim data showed no ARIA-E and encouraging biomarker signals.

Key figures

Guidance
PRECISE-AD unblinded 12-month topline data on track for Q1 2027; registrational study anticipated toward end of 2027
Runway
through 2027
Net loss q3
8161868
Cash position
44100000
Ga expense q3
1905389
Rd expense q3
6710035

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    PMN: ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing — AI Analysis | Signal8